Malaria Vaccine Development: Oxford and ReciBioPharm Extend Manufacturing Deal
November 10, 2025
-
5 min
5 Key Takeaways
-
1
Oxford and Recipharm are collaborating on malaria vaccine candidates R78C and RH
-
2
The vaccines target serious malaria infections through blood stage intervention.
-
3
Malaria is a complex disease with a varied life cycle making vaccine development challenging.
-
4
Over 249 million malaria cases and 608,000 deaths were reported in 202
-
5
Early safety profiles for the vaccine candidates appear promising, with scaling up for clinical evaluation underway.
The University of Oxford and Recipharm Advanced Bio have expanded their partnership to manufacture malaria vaccine candidates R78C and RH5.1 for phase I/II trials. Developed at Oxford's Draper Lab, these vaccines aim to address the significant global burden of malaria, which caused an estimated 249 million cases and 608,000 deaths in 2022. Key challenges in developing malaria vaccines include the complex life cycle of the parasite, requiring a multi-antigen approach for effective immunity. Promising results from preclinical studies have led to the transition into scalable manufacturing for clinical evaluation.
Listen Tab content
